Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PeptiDream Inc. (4587:JPX), powered by AI.
PeptiDream Inc. is currently trading at ¥925.1. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for PeptiDream Inc. on Alpha Lenz.
PeptiDream Inc.'s P/E ratio is -31.9.
“PeptiDream Inc. trades at a P/E of -31.9 (undervalued) with modest ROE of -6.9%.”
Ask for details →PeptiDream Inc. is a biotechnology firm that plays a pivotal role in the healthcare and pharmaceutical sectors. The company is particularly known for its innovative peptide drug discovery platform. This novel platform enables the development of highly specific and potent peptide-based therapeutics, targeting a broad range of medical conditions, from cancer to metabolic disorders. PeptiDream’s technology, which focuses on using advanced techniques in molecular biology and chemistry, allows for the design of peptides that can interact with targets that are traditionally difficult to engage with small molecules or antibodies. Operating within the competitive and rapidly-evolving biotechnology industry, PeptiDream Inc. frequently collaborates with global pharmaceutical companies to co-develop treatments and bring new drugs to market. These partnerships are crucial for enhancing the development pipeline and expanding the potential impact of their therapeutic discoveries. Established as a leader in peptide drug design, PeptiDream contributes significantly to medical advancements and offers substantial potential for introducing novel therapeutic solutions to unmet clinical needs. Its work in addressing complex biological targets underscores its importance in driving innovation within the pharmaceutical research community.
“PeptiDream Inc. trades at a P/E of -31.9 (undervalued) with modest ROE of -6.9%.”
Ask for details →PeptiDream Inc. (ticker: 4587) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 757 employees. Market cap is $119.6B.
The current price is 925.1 with a P/E ratio of -31.91x and P/B of 2.32x.
ROE is -6.92% and operating margin is -27.07%. Annual revenue is $18.5B.